These compounds may interact with:
Prolyl endopeptidase FAP
Potentially involved in: vitiligo; carcinoma; crohn's disease; diabetes mellitus; familial hemophagocytic lymphohistiocytosis 5; pharyngitis; adrenocortical carcinoma; breast cancer; breast carcinoma; cystic fibrosis; duchenne muscular dystrophy; ependymoma; gastric carcinoma; interstitial cystitis; intraductal papillary-mucinous adenoma (ipma); invasive ductal carcinoma; lung adenocarcinoma; lung cancer; malignant mesothelioma; non-small cell lung cancer
Disease data sourced from Pharos.